Compare FedEx Corporation (FDX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FedEx Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? FedEx Corporation trades at $290.91 (market cap $69.04B), while State Street SPDR S&P Biotech ETF trades at $153.66 (market cap $10.11B). The key difference: FedEx Corporation is far larger — about 6.8× State Street SPDR S&P Biotech ETF's market cap, and FedEx Corporation pays a 1.67% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold FedEx Corporation for 87 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| FDX | XBI | |
|---|---|---|
Market Cap | $69.04B | $10.11B |
Volume | 1,287,367 | 12,903,266 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $339.35 | $169.55 |
52-Week Low | $180.87 | $104.99 |
Typical Hold Time | 87 Days | 37 Days |
Enterprise Value | $98.68B | — |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FedEx (FDX) trades at $289.04, showing minimal daily change. The stock exhibits a bearish technical signal with key support at $288 and resistance at $290. Fundamentally, the company maintains stable profitability with a net income margin of 4.68% and a P/E ratio of 15.73, while recent earnings beats in Q4 2025 and Q1 2026 highlight operational strength. Positive developments include a $300 million electric truck order and shareholder approval of executive compensation, though rising fuel prices present a near-term headwind.
The outlook for FDX is cautiously optimistic, supported by analyst consensus favoring a buy rating with a $307.55 price target. Investment appeal lies in its reasonable valuation and dividend yield, but risks include margin pressure from fuel costs, competitive intensity, and macroeconomic sensitivity. The stock's trajectory will likely hinge on execution of cost initiatives and freight demand trends.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
